Non-Hodgkin Lymphoma

LOXO-305, an investigational, highly selective, non-covalent BTK inhibitor, demonstrated an investigator-assessed 63% objective response rate in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

December 7, 2020 - In high-risk patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, lisocabtagene maraleucel treatment resulted in a high rate of undetectable minimal residual disease with rapid and durable responses

December 6, 2020 - Odronextamab, is a novel CD20xCD3 bispecific antibody, continues to show intriguing antitumor activity and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, including those who have previously received chimeric antigen receptor T-cell therapy.

December 6, 2020 - The bispecific IgM antibody IGM-2323 shrank tumors in 9 of 14 patients with CD20-positive, relapsed/refractory non-Hodgkin lymphomas in preliminary results from a phase 1 clinical trial presented at the 2020 ASH Annual Meeting

December 5, 2020 - Engineering chimeric antigen receptors T cells to overcome CD58 loss may provide a path forward for patients with large B-cell lymphomas who do not respond to treatment with immunotherapy.

The anti-inducible T-cell co-stimulator monoclonal antibody MEDI-570 showed clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed/refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.

December 5, 2020 - VLS-101, a novel ROR1-targeted antibody-drug conjugate, demonstrated encouraging clinical efficacy, consistent pharmacokinetics, and a favorable safety profile in patients with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma.

December 5, 2020 - Axicabtagene ciloleucel demonstrated high rates of durable responses in patients with indolent non-Hodgkin lymphoma.

December 5, 2020 - Selinexor demonstrated a clinical benefit in patients with relapsed/refractory diffuse large B-cell lymphoma, regardless of age.

Drs Stilgenbauer and Ghia provide insight on initial treatment considerations for patients with newly diagnosed chronic lymphocytic leukemia.

Nirav N. Shah, MD, associate professor​, Medical College of Wisconsin, discusses ​the dosing of tandem receptor CAR T-cell therapy in B-cell malignancies.

Stephen A. Strickland, MD, BS, MS, MSCI, relays insightful questions from the audience to the speakers, who provided insight into how they are navigating the evolving treatment landscape of hematologic malignancies.

November 20, 2020 - The FDA has granted a priority review designation to a biologics license application for loncastuximab tesirine for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

November 17, 2020 - The review of the biologics license application for the CAR T-cell product lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma following at least 2 previous therapies has been delayed.

Nishitha M. Reddy, MD, MBBS, discusses the significance of the ECHELON-2 trial in peripheral T-cell lymphoma, the need for novel therapies for those with CD30-negative disease, and the excitement surrounding duvelisib in the relapsed/refractory setting.

Frontline treatment decisions for patients with follicular lymphoma can be guided by a general framework; the choice of therapy is often based on several factors such as indications of therapy, bulk of disease, comorbidities, and toxicity.

A panel of lymphoma experts discuss several novel agents for relapsed/ refractory diffuse large B-cell lymphoma, some of which have been recently approved.

The investigational wholly-owned allogeneic CAR T-cell therapy CTX110 demonstrated dose-dependent efficacy and responses in patients with relapsed/refractory CD19-positive B-cell malignancies.

Copanlisib in combination with rituximab prolonged progression-free survival in patients with non-Hodgkin lymphoma who relapsed following 1 or more previous lines of rituximab-based therapy.